R ett syndrome (MIM 312750) is a neurodevelopmental disorder affecting mainly girls that combines mental retardation, autism, and neurological features. 1 Amir and colleagues 2 identified as the genetic cause of Rett syndrome mutations in the X-linked methyl CpG-binding protein 2 gene (MECP2), which encodes the MeCP2 protein, that binds methylated DNA and is thought to repress transcription of target genes. Classically, patients with this syndrome present an apparently normal initial developmental period (6 to 18 months of age) followed by an arrest and then regression of development, with deceleration in head growth, psychomotor delay and loss of acquired social and motor skills, and appearance of stereotypies. 1 The atypical forms of the disorder may present as either milder or more severe phenotypes. Given the very low frequency of male cases with Rett syndrome, the disorder was initially thought of as an X-linked dominant disorder, usually fatal in males. However, the low frequency of male cases could also be due to the fact that most mutations in MECP2 occur de novo in paternal transmissions. 3 In the small number of males with Rett syndrome described in the literature, classical Rett syndrome is associated with (1) a somatic mosaicism of the mutation, (2) a Klinefelter syndrome (47, XXY), or (3) a hypomorphic MECP2 allele. [4] [5] [6] [7] As happens with other X-linked dominant disorders, the hemizygous males most often exhibit a more severe phenotype and most of the mutations that cause classical Rett in females originate a very different clinical presentation in males. 3, 8 The most common phenotype associated with MECP2 mutation in males is a severe neonatal encephalopathy (see supplementary review Table S1 ). 4, 8, [15] [16] [17] 20, 23, 24, 28 However, mutations in this gene have been identified in patients with X-linked mental retardation associated with neurological features, such as limb spasticity with truncal and facial hypotonia, 19, 26, 27, 29 with nonspecific mental retardation 12, 14, 30, 31 and autism. 32 MECP2 mutations have also been identified in male patients with language disorder and schizophrenia, 11 with an X-linked syndrome, including psychosis, pyramidal signs, and macro-orchidism, 13 and with Prader-Willi and Angelman syndrome-like phenotypes. 18, 22, 27 For this reason, in a research context, the molecular testing of MECP2 gene in males with a wide spectrum of neurodevelopmental disorders such as unexplained early neonatal death, neonatal encephalopathy, or mental retardation, with or without neurological signs, has been proposed, even in the absence of familial history of similar disease, to further characterize the role of MECP2 as an etiologic factor in this wide range of diseases.
The aim of the current study was to identify the extent to which mutations in the MECP2 gene could explain the neurodevelopmental phenotypes presented by a group of 28 male patients of Portuguese origin displaying neurodevelopmental phenotypes compatible with those previously associated with MECP2 mutations, including 13 patients with ''Rett-like'' features.
Material and Methods

Patients
The 28 Portuguese male patients selected for this study were sent to our laboratory by clinical geneticists, pediatricians, or pediatric neurologists to be tested for MECP2 gene mutations. A questionnaire asking for clinical, molecular, and familial information was filled in by the clinicians requesting the diagnosis; a summary of the clinical presentation for all the patients is presented in Table 1 . Analysis of this information suggested to us that 13 of the patients had a clinical presentation compatible with a variant form of Rett syndrome (Rett syndrome-like), according to the criteria defined by Hagberg and colleagues 33 (group I, patients 1 to 13 in Table  1 ); whereas the others did not fulfill the criteria but had clinical manifestations previously seen in MECP2 mutant males, namely mental retardation of unknown etiology with one or more of the following features: autism, microcephaly, epilepsy, manual apraxia, and/or stereotypies (group II, patients 14 to 28 in Table 1 ). Patients 1, 2, 4, 8, 9, 10, 16, 26, and 28 presented an epileptogenic encephalopathy. Patients 14 and 15 presented with visual and hearing deficits, not typical of Rett syndrome, and so they were not included in group I. Metabolic studies were performed for all patients and did not reveal any alterations. Informed consent for the genetic study was obtained from all patients or their legal representatives.
Molecular analysis:
Genomic DNA was extracted from peripheral blood leukocytes using the Puregene DNA isolation kit (Gentra, Minneapolis, Minn). The coding region and exon-intron boundaries of the MECP2 gene were amplified by polymerase chain reaction (PCR); the amplified fragments were automatically sequenced and analyzed for point mutations or small rearrangements. Sequence changes were confirmed by re-amplification with genomic DNA and sequencing in the opposite direction. The RD-PCR method 34 was used for the detection of large duplications of the MECP2 gene. Primers used, PCR mixtures and cyclic conditions, are available on request. Table 1 presents a summary of the clinical presentations of the patients we analyzed. The patients' age at the last observation ranged from 4 to 21 years (mean 11 years). Some of the patients had previous molecular exclusion of other clinical conditions and their karyotypes had all been assessed as normal ( Table 2 ). Analysis of the DNA sequence of the MECP2 gene in all patients (group I and group II) did not reveal any potentially pathogenic mutation. We found a silent mutation in the MECP2 gene in one patient (897C>T; T299T) and an intronic deletion of one nucleotide (IVS3-17delT) in another patient, both already described as polymorphisms in the literature (http://mecp2.chw.edu.au/mecp2/). We also searched for large duplications or deletions in the MECP2 gene in both groups of patients but did not find any alteration in the exons or gene dosage.
Results
Discussion
Male patients with neurodevelopmental disorders present a wide spectrum of phenotypes and share a combination of symptoms, which encompass mental retardation, autism, epilepsy, and movement disorders. In most cases the genetic basis of the pathology is unknown and MECP2 is an interesting candidate gene to be analyzed. Mutations in MECP2 are found in female patients with heterogeneous clinical presentations; contributing to this fact are the effects of X-chromosome inactivation patterns as well as a potentially significant influence of epistatic, epigenetic, or environmental modifiers. Furthermore, mutations known to be Rett syndrome-causing in females do not produce similar phenotypes in males, due to the X-linked dominance of the disorder 6 and possibly to differences in the above-mentioned modifier effects. The heterogeneity of phenotypes associated with MECP2 mutation in males (supplementary Table S1 ) opened the possibility that mutations in this gene could underlie a variety of X-linked neurodevelopmental phenotypes.
We were not able to identify any mutation in the MECP2 in our sample of boys with Rett syndromeoverlapping (Rett syndrome-like) phenotypes, including the large duplications of this gene, which were described to be frequent in mentally retarded males with progressive neurological symptoms. 29 Mutations in the noncoding regions of MECP2, introns and regulatory 5 0 untranslated region and 3 0 untranslated region, might have been missed since these regions were not covered in this study. However, although Shibayama et al 35 reported that 3 0 untranslated region variants in the MECP2 gene seemed to be more frequent in autism patients than in the general population, we have previously searched for mutations in the 3 0 untranslated region of the MECP2 gene in a group of Portuguese Rett-syndrome female patients and we did not find any pathogenic mutation 36 suggesting that this must be a rare cause of Rett syndrome.
Our data suggests that, prior to the indication of systematic molecular testing of MECP2 in all males with neurodevelopmental pathologies, the study of larger population series should be performed. In fact, the majority of male patients with Rett syndrome-like symptoms do not present mutations in the MECP2 gene, which is in favour of the hypothesis that mutations in other gene(s) may be involved in this disorder. 37 Even using a stricter phenotype definition, there are males with a clinical diagnosis of Rett syndrome without identified MECP2 mutation. 5 There are a number of genes in which mutations have been found in patients with pathologies that partially overlap Rett syndrome, which it would be interesting to test in patients with Rett syndrome or a Rett syndrome-like clinical presentation without a MECP2 mutation: neuroligin 3 and neuroligin 4, mutated in patients with autism, mental retardation or Asperger syndrome, 38 the aristalessrelated homeobox 39 and the serine/threonine kinase 9 genes, mutated in patients with West syndrome 40 and ubiquitin-protein ligase E3A (involved in Angelman syndrome) 41 are interesting candidate genes. Brain derived neurotrophic factor and distal-less homeobox 5; two downstream target genes of MeCP2 regulation, [42] [43] [44] would also be potentially important candidates for future analysis. Nevertheless the possibility remains that additional novel genes may be identified as the molecular basis of disease in these patients.
